FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, immunology and virology. Disclosed agent can be used as a bivalent, trivalent or tetravalent vaccine for preventing the disease caused by influenza A H1N1 virus, influenza A H3N2 virus, influenza B/Victori virus, influenza B/Yamagata virus. Described is an agent based on mRNA vector, where mRNA contains a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9 at 5’ end; an open reading frame encoding an influenza virus antigen; sequence SEQ ID NO: 6 or SEQ ID NO: 7 at 3’ end.
EFFECT: creation of safe immunobiological agent based on mRNA vector, which provides induction of immune response against influenza virus.
4 cl, 3 dwg, 8 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOBIOLOGICAL AGENT FOR INDUCING A COMPLEX IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS AND INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2836687C1 |
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 19 SEROTYPE AND METHOD OF ITS APPLICATION | 2023 |
|
RU2811791C1 |
| VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
| IMMUNOBIOLOGICAL AGENT FOR THERAPY OF ONCOLOGICAL DISEASES BASED ON mRNA VECTOR | 2024 |
|
RU2828631C1 |
| METHOD FOR FORMING IMMUNE SURVEILLANCE SYSTEM FOR TUMOUR CELLS IN MAMMAL BODY | 2024 |
|
RU2828654C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| mRNA-BASED VECTOR FOR INCREASED TARGET PROTEIN PRODUCTION IN MAMMALIAN CELLS (VARIANTS) | 2022 |
|
RU2792231C1 |
| NEUTRALIZING BINDING MOLECULES DIRECTED AGAINST INFLUENZA VIRUS, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2721706C2 |
| ENHANCER ELEMENTS CPMV | 2015 |
|
RU2699982C2 |
| INCREASING VARIABLE-FREE PARTICLES OUTPUT IN PLANTS | 2012 |
|
RU2682752C2 |
